Biohaven Q3 Loss Narrows as FDA Accepts Vyglxia NDA Resubmission
Biohaven Ltd. on October 29, 2026, reported a net loss of $129.3 million, or $0.86 per share, for the third quarter ended September 30, 2026, compared with a net loss of $173.4 million, or $1.64 per share, in the same period of 2025, and said the U.S. Food and Drug Administration has accepted for review the company's resubmitted new drug application for Vyglxia (troriluzole) in spinocerebellar ataxia. In its third-quarter 2026 results announcement, the company also detailed an exclusive…